Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)

Inclusion Criteria:

• The patient has a primary diagnosis of MDE, diagnosed according to DSM-5® confirmedusing the Mini International Neuropsychiatric Interview (MINI).
• The patient has had the current MDE for <12 months
• The patient has current comorbid Generalized Anxiety Disorder (GAD) according toDSM-5®. The diagnosis was made prior to the current MDE
• The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score ≥ 22 at the Baseline Visit
• The patient has a Hamilton Anxiety Rating Scale (HAM-A) score ≥ 20 at the BaselineVisit

Exclusion Criteria:

• The patient has any current psychiatric disorder or Axis I disorder (DSM-5® criteria),established as the primary diagnosis, other than MDD, as assessed using the MiniInternational Neuropsychiatric Interview (MINI) or another diagnostic interview.
• The patient has a history of previous major depressive episodes considered astreatment resistant, defined as inadequate response (incomplete or no therapeuticresponse) to two prior courses of at least 6 weeks of conventional antidepressantdrugs in adequate dosages or, the patient has treatment-resistant depression in theinvestigator's opinion. Other in- or exclusion criteria may apply